Form 8-K - Current report:
SEC Accession No. 0000950170-25-111319
Filing Date
2025-08-26
Accepted
2025-08-26 09:14:05
Documents
12
Period of Report
2025-08-26
Items
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K lctx-20250826.htm   iXBRL 8-K 48606
2 EX-9.1 lctx-ex9_1.htm EX-9.1 31506
3 GRAPHIC img193828089_0.jpg GRAPHIC 41113
  Complete submission text file 0000950170-25-111319.txt   247425

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT lctx-20250826.xsd EX-101.SCH 23883
14 EXTRACTED XBRL INSTANCE DOCUMENT lctx-20250826_htm.xml XML 4516
Mailing Address 2173 SALK AVENUE SUITE 200 CARLSBAD CA 92008
Business Address 2173 SALK AVENUE SUITE 200 CARLSBAD CA 92008 5105213390
Lineage Cell Therapeutics, Inc. (Filer) CIK: 0000876343 (see all company filings)

EIN.: 943127919 | State of Incorp.: CA | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)